Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib in Japanese Patients with Heterozygous Familial Hypercholesterolemia
NCT01824238Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of anacetrapib in heterozygous familial hypercholesterolemia (HeFH), sponsored by Merck & Co.. Started May 2013; status: completed.
02
Drugs
anacetrapib
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01824238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824238.